CDIA Statement Regarding Changes in FICO Pricing
WASHINGTON, Oct. 2, 2025 /PRNewswire/ — While the Direct License Program announced by FICO is positioned as a cost-cutting measure, it is simply not true.... Read more.
The Inner Circle acknowledges, Dr. Moumine Ballo as a Pinnacle Professional Member Inner Circle of Excellence
SAN JOSE, Calif., Oct. 2, 2025 /PRNewswire/ — Prominently featured in The Inner Circle, Dr. Moumine Ballo is recognized as a Pinnacle Professional Member Inner... Read more.
Vistra Marks Next Step in Acquisition of Gas Generation Fleet with Approval from the Federal Energy Regulatory Commission
IRVING, Texas, Oct. 2, 2025 /PRNewswire/ — Vistra (NYSE: VST) today announced it has received regulatory approval from the Federal Energy Regulatory Commission... Read more.
AIR Asset Management Exploring Opportunities in Pre-IPO Artificial Intelligence
CHICAGO, Oct. 2, 2025 /PRNewswire/ — AIR Asset Management (“AIR,” “the Firm”), a Chicago-based alternative investment manager, announced... Read more.
NetDocuments Announces Agreement to Acquire eDOCS from OpenText
Acquisition underscores NetDocuments’ singular focus on delivering the future of legal document management and AI-powered innovation LEHI, Utah, Oct. 2, 2025... Read more.
OpenSolar launches AI technology for solar professionals and completes $20m Equity Raise
OpenSolar to extend their technology investment in AI to support solar installers globally and accelerate the energy transition. SAN FRANCISCO, Oct. 2, 2025 /PRNewswire/... Read more.
OpenText to Strategically Divest Non-Core Unit for US$163 Million
Transaction accelerates announced strategy of divesting non-core businesses WATERLOO, ON, Oct. 2, 2025 /PRNewswire/ — Open Text Corporation (NASDAQ: OTEX),... Read more.
Emeren Group Announces Cancellation and Rescheduling of Extraordinary General Meeting
NORWALK, Conn., Oct. 2, 2025 /PRNewswire/ — Emeren Group Ltd (“Emeren” or the “Company“) (www.emeren.com) (NYSE: SOL), a leading global... Read more.
Graves’ Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight
The Graves’ orbitopathy market is undergoing rapid change, driven by advancements in targeted treatments. TEPEZZA (teprotumumab-trbw) remains the only approved... Read more.
Mistral Inc. and Uvision Inc. Secure a $982 Million Multi-Year IDIQ Contract with the U.S. Army for HERO 120 Loitering Munition
BETHESDA, Md., Oct. 2, 2025 /PRNewswire/ — Mistral Inc., a leading provider of advanced defense solutions, together with Uvision Inc. (formerly known as UVision... Read more.